Skip to main content
PEGASUS MERCANTILE INC. logo

PEGASUS MERCANTILE INC. — Investor Relations & Filings

Ticker · LOAN ISIN · CA70557Y2042 LEI · 529900BGK3BYC4VSF690 CSE Financial and insurance activities
Filings indexed 424 across all filing types
Latest filing 2024-06-14 Capital/Financing Update
Country CA Canada
Listing CSE LOAN

About PEGASUS MERCANTILE INC.

https://xtacytherapeutics.com/

Pegasus Mercantile Inc. is a diversified venture capital firm and prospect generator that provides financial, operational, and management assistance to high-growth companies. The firm specializes as an incubator for early-stage investments within the wellness consumer goods market, focusing on biotechnology, hemp, CBD, functional mushrooms, and psychedelics. Its investment strategy targets solutions for chronic pain, depression, and mental illness, often utilizing pioneering techniques such as micro-dosing organic and synthetic compounds. Pegasus Mercantile assists portfolio companies from startup through commercialization, specializing in navigating complex regulatory requirements, including clinical trials, patenting, and legislative approvals. The firm also provides debt financing facilities.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a short announcement (2209 characters) about a debt settlement involving the issuance of shares to creditors. It details the terms of the share issuance to settle outstanding accounts payable. There is no financial statement, comprehensive financial data, or detailed report content. The document is an update on financing activities, specifically about capital structure changes through share issuance to settle debt. This fits the definition of a Capital/Financing Update (CAP). It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or report publication announcement. Therefore, the classification is CAP with high confidence.
2024-06-14 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-05-29 English
Interim MD&A - English.pdf
Regulatory Filings
2024-05-29 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-05-29 English
News release - English.pdf
Regulatory Filings
2024-05-13 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended December 31, 2023. It explicitly states it is a 'Venture Issuer Basic Certificate' under Form 52-109FV2, certifying the review and fair presentation of the interim filings. The document does not contain the actual interim financial statements or substantive financial data but is a certification letter about those filings. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (2984 characters), and it is clearly a certification rather than the report itself.
2024-04-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.